CARsgen Reports Promising Early Results for Allogeneic BCMA CAR-T Therapy in Relapsed Primary Plasma Cell Leukemia
I'm PortAI, I can summarize articles.
CARsgen Therapeutics Holdings Ltd. has reported promising early results for its allogeneic BCMA-targeted CAR-T therapy, CT0596, in treating relapsed primary plasma cell leukemia (pPCL). Preliminary data from two enrolled patients showed both achieved stringent complete response post-infusion, with robust CAR-T cell expansion and manageable safety profiles. Adverse events included cytokine release syndrome and hematologic toxicities, but no significant organ toxicities were noted. These findings support further investigation of CT0596 in plasma cell neoplasms.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments